Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Regeneron Pharmaceuticals : Says FDA Approves Eylea Injection for All Diabetic Retinopathy Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/13/2019 | 03:15pm EDT

By Michael Dabaie

Regeneron Pharmaceuticals Inc. (REGN) said the Food and Drug Administration approved Eylea injection to treat all stages of diabetic retinopathy.

The company said Eylea improves diabetic retinopathy and prevents worsening disease that can lead to blindness. Diabetic retinopathy is the leading cause of blindness among working-aged American adults, Regeneron said.

The FDA approval of Eylea as a treatment for diabetic retinopathy was based on six-month and one-year results from Panorama, a randomized, multi-center, controlled Phase 3 trial that enrolled 402 patients.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
06/14REGENERON PHARMACEUTICALS : Says Early-Stage Results Positive for REGN1979 in Ly..
DJ
06/14REGENERON PHARMACEUTICALS : CD20xCD3 Bispecific REGN1979 Shows Positive Results ..
PR
05/23REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
PR
05/17REGENERON PHARMACEUTICALS : Updated Libtayo Results Reinforce Durable and Substa..
AQ
05/17SANOFI : - Updated Libtayo Results Reinforce Durable and Substantial Response Ra..
AQ
05/14REGENERON PHARMACEUTICALS : FDA Approves EYLEA Injection for Diabetic Retinopath..
AQ
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/08REGENERON PHARMACEUTICALS : Dupixent Approved for Severe Asthma by European Comm..
AQ
05/08SANOFI : - Dupixent Approved for Severe Asthma by European Commission
AQ
05/07REGENERON PHARMACEUTICALS : Regulation FD Disclosure (form 8-K/A)
AQ
More news
Financials ($)
Sales 2019 7 282 M
EBIT 2019 2 678 M
Net income 2019 1 896 M
Finance 2019 4 492 M
Yield 2019 -
P/E ratio 2019 18,26
P/E ratio 2020 15,29
EV / Sales 2019 3,92x
EV / Sales 2020 3,32x
Capitalization 33 042 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 388 $
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-18.28%32 744
GILEAD SCIENCES6.09%80 909
VERTEX PHARMACEUTICALS2.72%42 680
GENMAB10.45%10 857
SAREPTA THERAPEUTICS INC9.57%8 523
NEUROCRINE BIOSCIENCES, INC.17.52%7 500